Rottapharm Biotech is an R&D company dedicated to innovative drug discovery and development. Born as a research-and-technology-driven company, Rottapharm Biotech is the spin-off of the former R&D division of Rottapharm|Madaus, of which it retained the whole capabilities, infrastructures, and innovative drug discovery programs and assets.
Rottapharm Biotech operates with a mixed discovery model involving new chemical entities (small molecules) and biotherapeutics (monoclonal antibodies by a proprietary technology) against innovative targets.
Thanks to more than 50 years of experience in the management of both an R&D pipeline and a portfolio of marketed products, our scientists have gained large expertise in different therapeutic areas, especially rheumatology (osteoarthritis and rheumatoid arthritis), pain and inflammation, immunomodulation and immuno-oncology, selected oncology areas, and central nervous system. Such expertise in drug discovery and development includes: new target validation; development of animal models; pharmacological and pharmacokinetic characterization of new drug candidates; original formulation; and design of innovative clinical trials.
Our business model consists of a flexible approach where drug development is carried out mainly on internal proprietary discoveries, but also on external projects deriving from early-stage in-licensing or other forms of collaboration. Opportunities for out-licensing are considered during any development phase, but are pursued systematically once the clinical proof of concept has been achieved.